Full-Time

Technical Operations Scientist

Updated on 9/3/2026

Deadline 2/10/27
Lupin Pharmaceuticals

Lupin Pharmaceuticals

10,001+ employees

Global pharmaceutical manufacturer and distributor

Compensation Overview

$70k - $95k/yr

+ Discretionary performance bonus

Somerset County, NJ, USA

In Person

Bachelor's, Master's

Category
Biology & Biotech
Required Skills
Microsoft Office
Veeva
GMP
SAP Products
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's or master's degree in a scientific discipline is required.
  • At least 3 years of experience in benchwork or technical writing for a life science or pharmaceutical organization is required.
  • Working knowledge of SAP, Microsoft Office Suite, and electronic quality management systems such as TrackWise or Veeva is required.
  • Proficiency in Microsoft Word, PowerPoint, and Excel is required.
  • Proficient personal computer skills are required, including electronic mail, record keeping, routine database activity, word processing, spreadsheets, and graphics.
  • The role requires the ability to perform physical activities including standing, walking, sitting, using hands and fingers, reaching, talking, and hearing; occasional lifting of up to 15 pounds may be required in a manufacturing environment.
Responsibilities
  • Prepare and maintain detailed Manufacturing Batch Records and Packaging Batch Records.
  • Prepare and maintain Standard Operating Procedures for Manufacturing Science and Technology operations.
  • Author protocols and reports for scientific experiments, engineering studies, and process validations.
  • Run trial batches for new and commercial inline launches.
  • Collect and analyze data from scientific experiments and commercial batches using statistical tools and methods.
  • Support root cause analysis and problem-solving using lean principles.
  • Create and manage master recipes in SAP for manufacturing and packaging products at the Somerset facility.
  • Organize and manage Manufacturing Science and Technology documents in a shared drive.
  • Train staff on master batch records, protocols, and Standard Operating Procedures as needed.
  • Initiate quality management system records such as change controls, corrective and preventive actions, and deviations related to Manufacturing Science and Technology operations.
  • Coordinate with cross-functional departments to obtain timely approval and closure of quality management system records.
  • Perform other duties as assigned.
Desired Qualifications
  • Strong grammatical skills and effective oral and written communication skills.
  • The ability to adapt to changes in work duties, responsibilities, and requirements and manage the workload.
  • Strong interpersonal skills and the ability to work as part of a team with formulation scientists and other departments.
  • Detail-oriented, thorough, methodical, and able to organize and plan work while managing and prioritizing multiple tasks and meeting deadlines.
  • Good editorial and proofreading skills, including the ability to outline, draft, revise, and review documents.
  • The ability to perform numerous simple and complex tasks while maintaining overall objectives.
Lupin Pharmaceuticals

Lupin Pharmaceuticals

View

Lupin Limited develops and sells branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients across over 100 markets. It brings medicines to patients by designing formulations and APIs, manufacturing at 15 sites, and distributing through a global network, supported by 7 research centers. Its integrated model combines a broad product portfolio with dedicated manufacturing, diagnostics, digital health, and manufacturing services to serve multiple therapeutic areas. Its goal is to improve patient health outcomes by expanding access to high-quality medicines and strengthening its global research, manufacturing, and digital capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Mumbai, India

Founded

1968

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 FY27 sales rose 33.3% to INR 82,172 million, a company record.
  • Pitolisant, Sugammadex, Eribulin, and Revefenacin approvals broaden 2026 U.S. launch momentum.
  • August 2026 Tenpoint partnership expands ophthalmology revenues across Europe, the UK, and Switzerland.

What critics are saying

  • June 2026 prednisolone eye-drop recall hit 2.53 million bottles over foreign-substance contamination.
  • Ankleshwar received two FDA observations in March 2026, extending Lupin's compliance overhang.
  • Tolvaptan faces Apotex, Teva, and another entrant in September 2026, crushing pricing.

What makes Lupin Pharmaceuticals unique

  • Lupin is building a specialty care moat through VISUfarma and YUVEZZI in Europe.
  • Ranluspec became the only interchangeable ranibizumab biosimilar in U.S. vials and syringes.
  • Q1 FY27 record revenue came from complex launches, biosimilars, and 42% U.S. sales.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

15%
PR Newswire
Aug 20th, 2026
Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

PR Newswire
Aug 17th, 2026
Lupin receives US FDA approval for generic Pitolisant tablets

Lupin Limited has received final approval from the US Food and Drug Administration for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The FDA approved Lupin's tablets as bioequivalent to Wakix for the indications in the approved labelling. Lupin is a Mumbai-based global pharmaceutical company that distributes products in over 100 markets. The company specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and six research centres globally, employing over 26,000 professionals.

PR Newswire
Jul 30th, 2026
Lupin launches generic Sugammadex injection in US after FDA approval

Lupin Limited has received US FDA approval and launched Sugammadex Injection in the United States. The product is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex Injection is bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery. Lupin is a Mumbai-based pharmaceutical company with products distributed in over 100 markets. The firm specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centres globally, employing over 26,000 professionals.

Multibagg AI
Jul 2nd, 2026
Lupin subsidiary to acquire 43.38% stake in Philippines' MPPI for up to $39.6M by May 2026

Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

PR Newswire
Jun 26th, 2026
Lupin receives tentative US FDA approval for generic Enzalutamide tablets

Lupin Limited has received tentative approval from the US FDA for its Enzalutamide Tablets in 40mg, 80mg, 120mg and 160mg strengths. The 40mg and 80mg versions were approved as bioequivalent to Astellas' Xtandi Tablets. Whilst Xtandi traditionally comes in 40mg and 80mg strengths, Lupin's tentatively approved 120mg and 160mg formulations will offer healthcare providers and patients additional dosing options. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally. Lupin operates 15 manufacturing sites and seven research centres worldwide, employing over 24,000 professionals. The company specialises in branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments.